Dedicated to creating life-changing medicines for people with
limited or no options.

Research and Development

At Jazz, we use patient-centric innovation to drive our research and development (R&D) strategy, investment and growth. This starts with identifying unmet needs across our therapeutic areas of focus—neuroscience and oncology—and take the best discovery and development approach to solutions, whether that leverages our proprietary, industry-defining research platforms or our collaborations with leading investigators and bioscience companies.

We believe all people, including those who live with complex conditions, deserve new and better therapeutic options. Our teams use their expertise to lead clinical programs across sleep, epilepsy, movement disorders, psychiatry and neurodegenerative diseases, as well as blood and solid tumor cancers. We are committed to innovation, leveraging both our market-defining cannabinoid science capabilities and other proprietary platforms. As part of our commitment to patients with unmet needs, we continually work to expand the science behind our therapies, acquire rights to develop new medicines, and partner with researchers, academia and other industry leaders to advance molecules with great potential to create new or better standards of care.

Pipeline

PRE-CLINICAL
Undisclosed targets
Neuroscience
CombiPlex
Exploratory activities
JZP341
(Long-acting Erwinia asparaginase)1
ALL/other hematological malignancies
Pan-RAF Inhibitor program
Raf & Ras mutant tumors
Undisclosed targets
Ras/Raf/MAP kinase pathway1
Exosome targets
(NRAS and 3 others)1
Hematological malignancies/solid tumors
Defibrotide
Exploratory activities
Undisclosed targets
Cannabinoids
PHASE 1
JZP324
Oxybate extended-release formulation
CPX351
Low Intensity Dosing for higher risk MDS2
CPX351 + other approved therapies
  • R/R AML or HMA Failure MDS2
  • First-line, fit AML (Phase 1b)
  • Low Intensity Therapy for first-line, unfit AML (Phase 1b)
Additional Cannabinoids
Neonatal hypoxic-ischemic encephalopathy
Additional Cannabinoids
Neuropsychiatry targets

PHASE 2
JZP3853
Essential tremor (Phase 2b)
JZP1503
PTSD
Lurbinectedin3
Basket trial: advanced urothelial cancer, large cell neuroendocrine tumor of the lung, HRD+ cancers
CPX351
  • HR-MDS (EMSCO)4
  • Newly diagnosed older adults with HR-AML3,4
CPX351 + venetoclax
de novo or R/R AML2
Nabiximols3
PTSD
Additional Cannabinoids
Schizophrenia
Additional Cannabinoids
Autism spectrum disorders

PHASE 3
Lurbinectedin
1L treatment SCLC in combination with I/O agent3
CPX351
  • AML or HR-MDS >60 yrs (AML18)4
  • AML or HR-MDS >18 yrs (AML19)4
  • Newly diagnosed adults with standard- and HR-AML (AMLSG)4
  • Newly diagnosed <22 yrs with AML (COG)4
Cannabidiol3
EMAS

Nabiximols
MS spasticity

Nabiximols3
Spinal cord injury spasticity

REGULATORY
JZP2585
Idiopathic hypersomnia
JZP4586
(recombinant Erwinia asparaginase)
ALL/LBL
Neuroscience
Hematology/Oncology
Cannabinoids
1Partnered collaboration.
2Jazz & MD Anderson Cancer Center collaboration study.
3Planned.
4Cooperative group study.
5Pending FDA approval.
6FDA approval on June 30, 2021; plan to submit additional data to support U.S. label update.

Through Jazz’s patented CombiPlex® platform, Jazz is evaluating oncology combinations to support identification of clinical product candidate(s) and is leading a collaborative approach with partners to research and develop new therapies.